Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric VNS Study Supports Cyberonics’ Focus On Epilepsy Growth Strategy

This article was originally published in The Gray Sheet

Executive Summary

Cyberonics may expand use of its vagus nerve stimulation (VNS) therapy device to children with drug-resistant epilepsy aged 12 and younger, following positive results from a small study conducted by the Children's Hospital at The Cleveland Clinic
Advertisement

Related Content

Cyberonics Depression Study Yields Benefit In Treatment-Resistant Patients
Cyberonics Depression Study Yields Benefit In Treatment-Resistant Patients
Advertisement
UsernamePublicRestriction

Register

MT018374

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel